Last reviewed · How we verify
NCT05754762
Median Effective Dose of Remifentanil for the Prevention of Myoclonus Induced by Etomidate Injection
NA trial testing Remifentanil in Etomidate in 70 participants. Status unknown.
1 July 2023
Quick facts
| Lead sponsor | Yangzhou University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 70 |
| Start date | 1 March 2023 |
| Primary completion | 1 July 2023 |
| Estimated completion | 1 July 2023 |
Drugs / interventions tested
- Remifentanil — full drug profile →
Conditions studied
Sponsor
Yangzhou University
Who can join
Adults 18 to 70, any sex, with Etomidate or Myoclonus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Since its introduction in 1973, etomidate has been widely used in clinical anaesthesia, especially in haemodynamically unstable patients, as a new anaesthetic induction drug with the advantage of low circulatory and respiratory depression. When administered via intravenous injection, etomidate can cause adverse effects such as injection pain and myoclonus. The incidence of myoclonus is still reported to be as high as 50-80%. Myoclonus caused by etomidate may cause discomfort during induction of anaesthesia and reduce perioperative satisfaction, and may lead to syringe dislodgement, extravasation of the injected drug, swelling at the injection site, delayed induction of anaesthesia and, in severe cases, cardiovascular adverse events. Therefore, the myoclonus and limb retraction reactions caused by etomidate are a key concern for clinical anaesthesiologists and need to be addressed at a time when comfort anaesthesia is being promoted. The aim of this study was to reduce myoclonus produced by etomidate injection during induction of general anaesthesia in surgical patients and to investigate the half effective dose of remifentanil to reduce etomidate myoclonus.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05754762
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Remifentanil
Trials testing the same drug.
- NCT06564857 — Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation · Phase 4 · recruiting
- NCT07336628 — Propofol vs Remifentanil for Sedation in Gastroscopy · NA · active not recruiting
- NCT07301970 — Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients · recruiting
- NCT07092384 — Effect of Remifentanil on Pruritus and Paresthesia of Fospropofol Disodium Anesthesia · NA · completed
- NCT06958393 — Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery · Phase 4 · not yet recruiting
Other Yangzhou University trials
Trials by the same sponsor.
- NCT06517069 — Effect of TEAS Combined With Oxycodone on Postoperative Visceral Pain in Gynecologic Laparoscopic Patients · NA · recruiting
- NCT05936918 — Application of Transcutaneous Electrical Acupoint Stimulation in Laparoscopic Cholecystectomy · NA · unknown
- NCT05909696 — Median Effective Dose of Rocuronium for the Prevention of Myofibrillation Caused by the Injection of Succinylcholine · NA · completed
- NCT05932485 — Effect of Stellate Ganglion Block on New Atrial Fibrillation After Coronary Artery Bypass Grafting · NA · completed
- NCT06456710 — Effect of a Psychological Intervention on Stigma: a Randomized Controlled Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05754762 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yangzhou University
- Last refreshed: 6 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05754762.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing